Shanghai Haihe Pharmaceutical’s Oral Paclitaxel RMX3001 Wins NMPA Nod for Advanced Gastric Cancer
Shanghai Haihe Pharmaceutical Co., Ltd from China and its South Korean partner Daehwa Pharmaceutical have...
Drug
Eli Lilly’s Kisunla Secures Market Approval in Japan for Early Symptomatic Alzheimer’s
Eli Lilly & Co. (NYSE: LLY) has announced that its Alzheimer’s disease (AD) treatment, Kisunla...
Amgen’s Tepezza Receives Approval in Japan for Treating Thyroid Eye Disease
Amgen (NASDAQ: AMGN), a prominent biotechnology company based in the U.S., has announced that its...
Elevation Oncology’s Claudin 18.2 Targeting ADC Earns FDA Fast Track Designation for Gastric Cancer
Elevation Oncology, Inc. (NASDAQ: ELEV), a biopharmaceutical company based in the U.S., has announced that...
China Medical System’s Opzelura Cream Filing for Vitiligo Accepted by NMPA
China Medical System Holdings (CMS; HKG: 0867) has announced that its market filing for Opzelura...
Junshi Biosciences’ Toripalimab Secures EC Nod for Two Cancer Indications
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that it has received...
Allist Pharma’s Partner Abbisko Receives NMPA Green Light for NSCLC Drug Trial
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced that it has...
UCB’s Bimzelx Gains FDA Approval for Three Additional Autoimmune Indications
Belgium-based biopharmaceutical company UCB has announced that the US Food and Drug Administration (FDA) has...
HBOW Bio’s First-in-Class Tumor Imaging Drug NC527-X Receives NMPA Clinical Trial Approval
HBOW Bio, a precision oncology company supported by Sherpa Healthcare Partners, has secured clinical trial...
CDE’s BL-B01D1 on Track for Breakthrough Therapy Designations for EGFR Wild-Type and Mutant NSCLC
The Center for Drug Evaluation (CDE) has indicated on its website that two indications for...
Shanghai Fudan-Zhangjiang Enrolls First Patient in U.S. Phase II Study for Port Wine Stain Treatment
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505), a leading biopharmaceutical company based in...
Antengene’s Xpovio Receives NDA Approval in Thailand for Multiple Myeloma Treatment
Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced that it...
Wuhan YZY Biopharma Presents M701 Interim Results at 2024 ESMO Congress for NSCLC-Related Pleural Effusion
Wuhan YZY Biopharma Co., Ltd (HKG: 2496), a biopharmaceutical company based in China, has announced...
Allist Pharmaceuticals’ EGFR Inhibitor AST2303 Approved for Clinical Trial in NSCLC by NMPA
Allist Pharmaceuticals Inc. (SHA: 688578), a Shanghai-based pharmaceutical company, has announced that it has received...
Haisco Pharmaceutical’s HSK21542 for Itching in Dialysis Patients Receives NMPA Review
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a prominent Chinese pharmaceutical company, has announced that...
CDE Lists Five Drugs and One Companion Diagnostic for Priority Review Status
The Center for Drug Evaluation (CDE) has indicated on its website that five investigational drugs...
Frontera Therapeutics Receives FDA Approval for Phase II Study of First Chinese rAAV Gene Therapy
Frontera Therapeutics, Inc., a Sino-US biopharmaceutical company, has announced that it has received approval from...
Sanofi’s Sarclisa Secures FDA Approval for First-Line Multiple Myeloma Treatment
Sanofi (EPA: SAN; NASDAQ: SNY) has announced that the US Food and Drug Administration (FDA)...
Novo Nordisk’s Obesity Drug Monlunabant Phase IIa Results Lead to Share Price Drop
Novo Nordisk (NYSE: NVO), a Danish pharmaceutical company, has reported Phase IIa trial results for...
Sichuan Biokin’s Multi-Specific Antibody GNC-077 Gets NMPA Nod for Advanced Solid Tumor Clinical Trial
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a biopharmaceutical company based in China, has announced...